A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

After starting therapy for psoriasis, Asempa usually has a follow-up visit at 3 to 4 months. Patient feedback at that point carries a lot of weight with respect to next steps.

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

How Does Psoriasis Increase Your Risk of Developing Other Conditions? Psoriasis is much more than a skin condition. Though it ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Key Takeaways Psoriasis makes skin cells grow too fast, forming thick, scaly patchesGenes plus triggers like stress, ...

Low testosterone and limited sleep emerged as key, independent contributors to psoriasis risk, revealing modifiable targets ...